<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197440</url>
  </required_header>
  <id_info>
    <org_study_id>N-20190062</org_study_id>
    <nct_id>NCT04197440</nct_id>
  </id_info>
  <brief_title>Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch</brief_title>
  <official_title>Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this experiment, the experimenter wish to create a new model of itch based on the
      substance BAM8-22 (Bovine Adrenal Medulla), which is found naturally in the human body and
      which has proved to evoke itch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With this experiment, the experimenter wish to create a new model of itch based on the
      substance BAM8-22 (Bovine Adrenal Medulla), which is found naturally in the human body and
      which has proved to evoke itch.To explore and validate the dose-response features of a of
      this new itch model based on BAM8-22.

      The experimenter will also characterize the sensory quality and temporary aspects of BAM8-22
      skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>superficial blood perfusion</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>is measured by a speckle contrast imager (FLPI, Moor Instruments, England)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Warm Detection Threshold, and Heat Pain threshold</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold Detection Threshold and Cold Pain threshold</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain supra-threshold heat Stimuli</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>the tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alloknesis</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>is measured by using a mildy pruritic, non-painful von Frey filaments of a predetermined intensity (generally 5-30 milliNewton of force)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mechanical pain threshold and sensitivity</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>is performed using a pin-prick set (Aalborg University). The set consists of 8 needles each having a diameter of 0,6 mm and different force applications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>itch rating</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>the subject will rate the itch for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates &quot;no itch&quot; and 100 indicates &quot;worst imaginable itch&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain rating</measure>
    <time_frame>change from baseline, up to 10 minutes after the first session</time_frame>
    <description>the subject will rate the pain for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates &quot;no pain&quot; and 100 indicates &quot;worst imaginable pain&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Itch</condition>
  <arm_group>
    <arm_group_label>Bam8-22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPT pricks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 2mg/ml</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop</description>
    <arm_group_label>Bam8-22</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 1mg/ml</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop</description>
    <arm_group_label>Bam8-22</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 0.5 mg/ml</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop</description>
    <arm_group_label>Bam8-22</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop</description>
    <arm_group_label>Bam8-22</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 with 1 SPT</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop</description>
    <arm_group_label>SPT pricks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 with 5 SPT</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop</description>
    <arm_group_label>SPT pricks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 with 25 SPT</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop</description>
    <arm_group_label>SPT pricks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAM8-22 with inactivate cowhage spicules</intervention_name>
    <description>20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules</description>
    <arm_group_label>SPT pricks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  18-60 years

          -  Speak and understand English

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Drug addiction defined as any use of cannabis, opioids or other drugs

          -  Previous or current history of neurological, dermatological, immunological
             musculoskeletal, cardiac disorder or mental illnesses that may affect the results
             (e.g. neuropathy, muscular pain in the upper extremities, etc.)

          -  Moles, wounds, scars or tattoos in the area to be treated or tested

          -  Lack of ability to cooperate •

          -  Current use of medications that may affect the trial such as antihistamines and pain
             killers.

          -  Skin diseases

          -  Consumption of alcohol or painkillers 24 hours before the study days and between these
             - Acute or chronic pain •

          -  Participation in other trials within 1 week of study entry (4 weeks in the case of
             pharmaceutical trials)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giulia Erica Aliotta</last_name>
    <phone>+45 50290580</phone>
    <email>gea@hst.aau.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Giulia Erica Aliotta</last_name>
      <phone>50290580</phone>
      <email>gea@hst.aau.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Giulia Erica Aliotta</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

